Menopause
From the Journals
Progesterone might benefit women in perimenopause
The best management for symptoms in perimenopause is an often-neglected topic of research.
Clinical Review
2023 Update on menopause
From the Journals
HT, even short-term use, linked to dementia risk in women
Short-term and cyclical use of estrogen and progestin therapy for menopausal symptoms is linked to an increased risk of dementia.
Commentary
Does ‘skeletal age’ describe fracture impact on mortality?
Mortality risk may be related to patients not fully understanding the consequence of a fragility fracture.
Conference Coverage
A ‘one-stop shop’: New guidance on hormones and aging
Part of what we need to do is [provide] the evidence that we have, which includes evidence of when not to prescribe as well as [when] to prescribe...
Commentary
A new nonhormonal option for menopausal hot flashes: What prescribers should know
In two phase 3 clinical trials, fezolinetant 45 mg reduced the frequency of vasomotor symptoms by about 65%.
From the Journals
Hormone therapies still ‘most effective’ in treating menopausal vasomotor symptoms
Clinicians should individualize menopause care to each patient.
From the Journals
Nitroglycerin patches do not improve menopause symptoms
“The menopause field is still lacking in effective treatment approaches that don’t involve hormones,” said Dr. Alison Huang.
Feature
Menopause and long COVID: What women should know
Women at midlife who have long COVID seem to get specific, and severe, symptoms, including brain fog, fatigue, new-onset dizziness, and difficulty...
Conference Coverage
Should you prescribe bioidentical hormones for menopause?
“They’re being hyped as safer and more effective when in reality, we don’t have any studies that show that information.”
Latest News
FDA approves new drug to manage menopausal hot flashes
Fezolinetant (Veozah) targets the neural activity behind moderate to severe vasomotor symptoms.